top of page

Search

habcfoundationuk

May 10, 20231 min read

Great news that Synapix Bio have secured £13.2m to fund clinical trials for H-ABC/Tubb4a!

Oxford biotech firm secures £13.2m to develop first treatment for rare, incurable, deadly disease. (synaptixbio.com)

Recent Posts

Addressing the Funding Crisis for Special Needs Education in the UK

Being a parent of a child suffering from Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum (H-ABC), a condition caused by...

Dan Williams interviewed for prestigious journal - Major International Clinical Trials feature showcases SynaptixBio story

BBC Interview Tubb4a Family

Comments

bottom of page